Translate Bio

78 articles about Translate Bio

• 

  A Look at the Biggest Biopharma Stories of 2021

  1/6/2022

  Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
• 

  Why Flu Vaccines are Recommended Despite Low Efficacy

  11/8/2021

  While some get the jab faithfully each flu season, about half of the American population declines, likely over doubts of the vaccine’s effectiveness and necessity.

• Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sep 08, 2021

  9/8/2021

  Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees.

• Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced financial results for the second quarter ended June 30, 2021 and reviewed recent corporate updates.

• Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development

  8/3/2021

  As part of Sanofi’s endeavor to accelerate the application of messenger RNA to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio, a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion.

• 

  Sanofi Cements mRNA Position with $3.2 Billion Translate Bio Deal

  8/3/2021

  With its acquisition, Sanofi aims to establish a firm toehold in the mRNA space by integrating dedicated research and development capabilities, chemistry, manufacturing and controls. 

• Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - July 07, 2021

  7/7/2021

  Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on July 6, 2021, the Company granted non-qualified stock options to purchase an aggregate of 177,400 shares of the Company’s common stock to nine new employees.

• 

  Is an mRNA Flu Vaccine on the Horizon?

  6/23/2021

  The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.

• Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine

  6/22/2021

  Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio, a clinical-stage messenger RNA therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.

• Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 09, 2021

  6/9/2021

  Translate Bio reported that on June 7, 2021, the Company granted non-qualified stock options to purchase an aggregate of 238,200 shares of the Company’s common stock to fifteen new employees.

• Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program

  6/7/2021

  -- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks --

• Translate Bio to Participate in Upcoming Investor Conferences - May 24, 2021

  5/24/2021

  Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced that the Company will participate in the following upcoming investor conferences

• Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference

  5/18/2021

  – Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into IND-enabling studies in 2H 2021

• Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update

  5/6/2021

  Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year

• Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 05, 2021

  5/5/2021

  Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on May 3, 2021, the Company granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company’s common stock to six new employees.

• Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit

  4/28/2021

  Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 10:30 a.m. EST.

• Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Apr 20, 2021

  4/20/2021

  Translate Bio reported that on April 19, 2021, the Company granted non-qualified stock options to purchase an aggregate of 201,800 shares of the Company’s common stock to Brendan Smith, the newly hired Chief Financial Officer of Translate Bio.

• Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines

  4/19/2021

  -- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy demonstrated in Syrian Golden Hamster challenge model under single and two-dose vaccination regimens of MRT5500 -- -- MRT5500 developed under a collaboration agreement with Sanofi Pasteur; Phase 1/2 clinical trial underway with clinical data anticipated in the third quarter of 2021 --

• Translate Bio Announces Key Leadership Additions and Promotions

  4/19/2021

  - - Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringing strategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary programs, manufacturing and financial operations with a goal of advancing platform, preclinical and clinical milestones --

• Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Apr 07, 2021

  4/7/2021

  Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on April 5, 2021, the Company granted non-qualified stock options to purchase an aggregate of 111,800 shares of the Company’s common stock to fourteen newly hired employees.